The shares are listed on the Nasdaq Global Market

Davis Polk advised the sales agent in connection with an SEC-registered at-the-marketing offering program by InflaRx N.V. of up to an aggregate offering price of $75 million of its ordinary shares. The ordinary shares are listed on the Nasdaq Global Market under the symbol “IFRX.”

InflaRx is a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system. InflaRx is committed to applying its proprietary anti-C5a / C5aR technologies to discover, develop and commercialize first-in-class, highly potent, and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR.

The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associates Michael Schuster and Kanger Jin. Partner David R. Bauer and associate Shreya R. Kundur provided intellectual property advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post